Skip to contentT
TuHURA Biosciences, Inc.
T
HURATuHURA Biosciences, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$9.22M-$9.22MN/M vs Q2 2025 EPS Diluted-$0.14-$0.14N/M vs Q2 2025 Operating Cash Flowderived-$8,633,599N/M Free Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TuHURA Biosciences, Inc. · CIK 1498382 · Engraved from SEC EDGAR
derived
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end